- Virtual
Adolescent Meningococcal Vaccines: Impact and Potential Changes
Learn more about STAT Brand Studio and partner with us for your next event!
Where
Virtual
When
{{getUserDateTimezone("1721840400").singleDate}}
{{getUserDateTimezone("1721840400").time}} - {{getUserDateTimezone("1721842200").time}} {{getClientTimezoneName()}}
About
Invasive meningococcal disease (IMD) is rare but devastating. The CDC’s Advisory Committee on Immunization Practices (ACIP) is considering changes to the adolescent meningococcal vaccination schedule that could impact immunization policies. STAT Brand Studio discusses these potential revisions with Richard H. Hughes IV, Will Humble, and Leslie Maier, exploring the importance of school vaccination requirements and potential effects of schedule changes on public health and equity.
Moderator
Jesse McQuarters, Branded Content Editor at STAT
Speakers
Richard H. Hughes IV, JD, MPH, Partner at Epstein, Becker & Green
Richard H. Hughes IV, JD, MPH, is a partner at Epstein, Becker & Green and a professorial lecturer in law at The George Washington University Law School and a nationally recognized vaccine thought leader who has led many efforts to expand access to vaccines and preventive services and improve public health outcomes.
Will Humble, Executive Director, Arizona Public Health Association
Will Humble is the Executive Director for the Arizona Public Health Association. His 35 years in public health included more than 2 decades at the Arizona Department of Health Services, where he served in various capacities including as the Agency Director from 2009 to 2015.
Leslie Maier, Advocate
Leslie Maier lost her son Chris, a high school senior who died from meningococcal disease at age 17. Leslie has been a fierce advocate for meningitis awareness and prevention. Her accomplishments include working with the Arizona Department of Health to make Arizona the first state to mandate vaccination for 11-12-year-olds.
In Partnership with
STAT editorial staff were not involved in the creation or execution of this event.
Upcoming Events
The immune-checkpoint inhibitor market alone was worth $15.5B in 2023. But could new diagnostics help it exceed its $53.5B predicted value i…
Join us in Boston or virtually October 16 – 17 at the 2024 STAT Summit for discussions on the latest breakthroughs in health & medicin…